Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04497597




Registration number
NCT04497597
Ethics application status
Date submitted
30/07/2020
Date registered
4/08/2020
Date last updated
7/06/2024

Titles & IDs
Public title
A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Scientific title
Upadacitinib Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Moderate to Severe Rheumatoid Arthritis Patients in Real-World Practice (UPHOLD)
Secondary ID [1] 0 0
P20-095
Universal Trial Number (UTN)
Trial acronym
UPHOLD
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis (RA) 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Participants receiving Upadacitinib - Participants receiving Upadacitinib for moderate to severe rheumatoid arthritis (RA).
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Who Achieve Remission
Timepoint [1] 0 0
At Month 6
Primary outcome [2] 0 0
Percentage of Participants Who Achieve Remission at 6 Months and Maintain Remission
Timepoint [2] 0 0
At Month 12
Secondary outcome [1] 0 0
Percentage of Participants Who Achieve Remission at 6 Months and Maintain Remission
Timepoint [1] 0 0
At Month 24
Secondary outcome [2] 0 0
Percentage of Participants Who Achieve Low Disease Activity (LDA) at 6 months that maintain LDA
Timepoint [2] 0 0
Through Month 24
Secondary outcome [3] 0 0
Percentage of Participants Who Achieve Remission at 3 Months and Maintain Remission
Timepoint [3] 0 0
Through Month 24
Secondary outcome [4] 0 0
Percentage of Participants Who Achieve Remission at 6 Months and Maintain Remission Grouped by Glucocorticoid Dose
Timepoint [4] 0 0
At Month 12
Secondary outcome [5] 0 0
Percentage of Participants Who Achieve LDA at 3 months that maintain LDA Grouped by Glucocorticoid Dose
Timepoint [5] 0 0
Through Month 6
Secondary outcome [6] 0 0
Percentage of Participants in LDA that Achieve Glucocorticoid Dose <5 mg/Day Per Visit
Timepoint [6] 0 0
Through Month 24
Secondary outcome [7] 0 0
Percentage of Participants in Remission that Achieve Glucocorticoid Dose <5 mg/Day Per Visit
Timepoint [7] 0 0
Through Month 24
Secondary outcome [8] 0 0
Percentage of Participants Who Achieved a Glucocorticoid Dose <5 mg/Day Without Conventional Synthetic Disease Modifying Anti Rheumatic Drug (csDMARD) Intensification
Timepoint [8] 0 0
At Month 6
Secondary outcome [9] 0 0
Percentage of Participants Who Initiated Upadacitinib as Combination Therapy (csDMARD +/- Glucocorticoids) That Moved to Monotherapy (+/- Glucocorticoids)
Timepoint [9] 0 0
Through Week 24
Secondary outcome [10] 0 0
Of the Participants Initiating Upadacitinib as Combination Therapy (csDMARD +/- Glucocorticoids) and Achieve Remission at 6 months, the Percentage of Participants that Maintain Remission Grouped by Maintenance of Combination Therapy Strategy
Timepoint [10] 0 0
Through Month 24
Secondary outcome [11] 0 0
Of the Participants Initiating Upadacitinib as Combination Therapy (csDMARD +/- Glucocorticoids) and Achieve LDA at 6 months, the Percentage of Participants that Maintain LDA Grouped by Maintenance of Combination Therapy Strategy
Timepoint [11] 0 0
Through Month 24
Secondary outcome [12] 0 0
Of the Participants Initiating Upadacitinib as Monotherapy Therapy (+/- Glucocorticoids) and Achieve Remission at 6 months, the Percentage of Participants that Maintain Remission Grouped by Maintenance of Monotherapy
Timepoint [12] 0 0
Through Month 24
Secondary outcome [13] 0 0
Of the Participants Initiating Upadacitinib as Monotherapy Therapy (+/- Glucocorticoids) and Achieve LDA at 6 months, the Percentage of Participants that Maintain LDA Grouped by Maintenance of Monotherapy
Timepoint [13] 0 0
Through Month 24
Secondary outcome [14] 0 0
Percentage of Participants Who Do Not Achieve Remission at Any Point in the Study
Timepoint [14] 0 0
Through Month 24
Secondary outcome [15] 0 0
Time to the Discontinuation of Upadacitinib
Timepoint [15] 0 0
Through Month 24
Secondary outcome [16] 0 0
Time to First Treatment Adjustment
Timepoint [16] 0 0
Baseline (Month 0) Through Month 24
Secondary outcome [17] 0 0
Percentage of Participants Achieving LDA Grouped by Therapy Strategy
Timepoint [17] 0 0
Through Month 24
Secondary outcome [18] 0 0
Percentage of Participants Achieving Remission Grouped by Therapy Strategy
Timepoint [18] 0 0
Through Month 24
Secondary outcome [19] 0 0
Change in Medication Burden Treatment Burden Questionnaire (TBQ) in Participants, Grouped by Therapy Strategy
Timepoint [19] 0 0
Through Week 24
Secondary outcome [20] 0 0
Change in Physical Function Health Assessment Questionnaire - Disability Index (HAQ-DI) in Participants, Grouped by Therapy Strategy
Timepoint [20] 0 0
Baseline (Month 0) Through Month 24
Secondary outcome [21] 0 0
Change in Pain Visual Analogue Scale (VAS) in participants, Grouped by Therapy Strategy
Timepoint [21] 0 0
Baseline (Month 0) Through Month 24
Secondary outcome [22] 0 0
Change in Morning Stiffness in Participants, Grouped by Therapy Strategy
Timepoint [22] 0 0
Baseline (Month 0) Through Month 24
Secondary outcome [23] 0 0
Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) in Participants, Grouped by Therapy Strategy
Timepoint [23] 0 0
Baseline (Month 0) Through Month 24

Eligibility
Key inclusion criteria
* Confirmed diagnosis of moderate to severe active Rheumatoid Arthritis (RA).
* Physician decision on patient treatment with upadacitinib must have been reached prior to and independently of recruitment in the study.
* Upadacitinib prescribed in accordance to the applicable approved label and local regulatory and reimbursement policies.
* French Participants Only: Taking oral glucocorticoids =5 mg/day of prednisone or equivalent for at least 3 months prior to study start.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Prior treatment with Upadacitinib.

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
16/10/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
15/05/2024
Sample size
Target
Accrual to date
Final
1532
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
Genesis Research Services /ID# 224060 - Broadmeadow
Recruitment hospital [2] 0 0
BJC Health /ID# 223884 - Paramatta
Recruitment hospital [3] 0 0
Private Practice - Scott Walter Graf /ID# 223958 - Adelaide
Recruitment hospital [4] 0 0
Emeritus Research /ID# 223883 - Camberwell
Recruitment hospital [5] 0 0
Joint West Rheumatology /ID# 223886 - Murdoch
Recruitment postcode(s) [1] 0 0
2292 - Broadmeadow
Recruitment postcode(s) [2] 0 0
2150 - Paramatta
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
3124 - Camberwell
Recruitment postcode(s) [5] 0 0
6150 - Murdoch
Recruitment outside Australia
Country [1] 0 0
Argentina
State/province [1] 0 0
Buenos Aires
Country [2] 0 0
Argentina
State/province [2] 0 0
Ciudad Autonoma De Buenos Aires
Country [3] 0 0
Argentina
State/province [3] 0 0
Santa Fe
Country [4] 0 0
Argentina
State/province [4] 0 0
Tucuman
Country [5] 0 0
Argentina
State/province [5] 0 0
Cordoba
Country [6] 0 0
Argentina
State/province [6] 0 0
Santiago Del Estero
Country [7] 0 0
Austria
State/province [7] 0 0
Kaernten
Country [8] 0 0
Austria
State/province [8] 0 0
Niederoesterreich
Country [9] 0 0
Austria
State/province [9] 0 0
Steiermark
Country [10] 0 0
Austria
State/province [10] 0 0
Wien
Country [11] 0 0
Belgium
State/province [11] 0 0
Bruxelles-Capitale
Country [12] 0 0
Belgium
State/province [12] 0 0
Hainaut
Country [13] 0 0
Belgium
State/province [13] 0 0
Limburg
Country [14] 0 0
Belgium
State/province [14] 0 0
Namur
Country [15] 0 0
Belgium
State/province [15] 0 0
Oost-Vlaanderen
Country [16] 0 0
Belgium
State/province [16] 0 0
Aalst
Country [17] 0 0
Belgium
State/province [17] 0 0
Brugge
Country [18] 0 0
Belgium
State/province [18] 0 0
Genk
Country [19] 0 0
Belgium
State/province [19] 0 0
Gistel
Country [20] 0 0
Belgium
State/province [20] 0 0
Liege
Country [21] 0 0
Belgium
State/province [21] 0 0
Sijsele
Country [22] 0 0
France
State/province [22] 0 0
Aisne
Country [23] 0 0
France
State/province [23] 0 0
Allier
Country [24] 0 0
France
State/province [24] 0 0
Alpes-Maritimes
Country [25] 0 0
France
State/province [25] 0 0
Bas-Rhin
Country [26] 0 0
France
State/province [26] 0 0
Bouches-du-Rhone
Country [27] 0 0
France
State/province [27] 0 0
Calvados
Country [28] 0 0
France
State/province [28] 0 0
Charente
Country [29] 0 0
France
State/province [29] 0 0
Cote-d Or
Country [30] 0 0
France
State/province [30] 0 0
Deux-Sevres
Country [31] 0 0
France
State/province [31] 0 0
Doubs
Country [32] 0 0
France
State/province [32] 0 0
Essonne
Country [33] 0 0
France
State/province [33] 0 0
Finistere
Country [34] 0 0
France
State/province [34] 0 0
Franche-Comte
Country [35] 0 0
France
State/province [35] 0 0
Gironde
Country [36] 0 0
France
State/province [36] 0 0
Haute-Garonne
Country [37] 0 0
France
State/province [37] 0 0
Hautes-Pyrenees
Country [38] 0 0
France
State/province [38] 0 0
Hauts-de-France
Country [39] 0 0
France
State/province [39] 0 0
Herault
Country [40] 0 0
France
State/province [40] 0 0
Ile-de-France
Country [41] 0 0
France
State/province [41] 0 0
Isere
Country [42] 0 0
France
State/province [42] 0 0
Loire
Country [43] 0 0
France
State/province [43] 0 0
Marne
Country [44] 0 0
France
State/province [44] 0 0
Moselle
Country [45] 0 0
France
State/province [45] 0 0
Oise
Country [46] 0 0
France
State/province [46] 0 0
Paris
Country [47] 0 0
France
State/province [47] 0 0
Pays-de-la-Loire
Country [48] 0 0
France
State/province [48] 0 0
Provence-Alpes-Cote-d Azur
Country [49] 0 0
France
State/province [49] 0 0
Rhone
Country [50] 0 0
France
State/province [50] 0 0
Savoie
Country [51] 0 0
France
State/province [51] 0 0
Somme
Country [52] 0 0
France
State/province [52] 0 0
Tarn
Country [53] 0 0
France
State/province [53] 0 0
Vendee
Country [54] 0 0
France
State/province [54] 0 0
Aix En Provence Cedex 1
Country [55] 0 0
France
State/province [55] 0 0
Annecy
Country [56] 0 0
France
State/province [56] 0 0
Arras
Country [57] 0 0
France
State/province [57] 0 0
Boulogne sur Mer
Country [58] 0 0
France
State/province [58] 0 0
Cahors
Country [59] 0 0
France
State/province [59] 0 0
Chambray Les Tours
Country [60] 0 0
France
State/province [60] 0 0
Cholet
Country [61] 0 0
France
State/province [61] 0 0
Clamart
Country [62] 0 0
France
State/province [62] 0 0
Clermont Ferrand
Country [63] 0 0
France
State/province [63] 0 0
Corbeil Essonnes
Country [64] 0 0
France
State/province [64] 0 0
Haguenau
Country [65] 0 0
France
State/province [65] 0 0
La Rochelle
Country [66] 0 0
France
State/province [66] 0 0
Le Puy en Velay
Country [67] 0 0
France
State/province [67] 0 0
Lille
Country [68] 0 0
France
State/province [68] 0 0
Lyon
Country [69] 0 0
France
State/province [69] 0 0
Monaco
Country [70] 0 0
France
State/province [70] 0 0
Montauban
Country [71] 0 0
France
State/province [71] 0 0
Mulhouse
Country [72] 0 0
France
State/province [72] 0 0
Orléans
Country [73] 0 0
France
State/province [73] 0 0
Rennes CEDEX 2
Country [74] 0 0
France
State/province [74] 0 0
Rouen
Country [75] 0 0
France
State/province [75] 0 0
Saint-Mandé cedex
Country [76] 0 0
France
State/province [76] 0 0
Sainte Maxime
Country [77] 0 0
France
State/province [77] 0 0
St Nazaire
Country [78] 0 0
France
State/province [78] 0 0
St-Priest-en-Jarez
Country [79] 0 0
France
State/province [79] 0 0
Strasbourg
Country [80] 0 0
Germany
State/province [80] 0 0
Baden-Wuerttemberg
Country [81] 0 0
Germany
State/province [81] 0 0
Brandenburg
Country [82] 0 0
Germany
State/province [82] 0 0
Baden-baden
Country [83] 0 0
Germany
State/province [83] 0 0
Bamberg
Country [84] 0 0
Germany
State/province [84] 0 0
Berlin
Country [85] 0 0
Germany
State/province [85] 0 0
Braunschweig
Country [86] 0 0
Germany
State/province [86] 0 0
Cologne
Country [87] 0 0
Germany
State/province [87] 0 0
Ehringshausen
Country [88] 0 0
Germany
State/province [88] 0 0
Erfurt
Country [89] 0 0
Germany
State/province [89] 0 0
Gommern
Country [90] 0 0
Germany
State/province [90] 0 0
Hamburg
Country [91] 0 0
Germany
State/province [91] 0 0
Heidelberg
Country [92] 0 0
Germany
State/province [92] 0 0
Leipzig
Country [93] 0 0
Germany
State/province [93] 0 0
Leverkusen
Country [94] 0 0
Germany
State/province [94] 0 0
Magdeburg
Country [95] 0 0
Germany
State/province [95] 0 0
Pfarrkirchen
Country [96] 0 0
Germany
State/province [96] 0 0
Planegg
Country [97] 0 0
Germany
State/province [97] 0 0
Trier
Country [98] 0 0
Greece
State/province [98] 0 0
Achaia
Country [99] 0 0
Greece
State/province [99] 0 0
Attiki
Country [100] 0 0
Greece
State/province [100] 0 0
Evros
Country [101] 0 0
Greece
State/province [101] 0 0
Kriti
Country [102] 0 0
Greece
State/province [102] 0 0
Athens
Country [103] 0 0
Greece
State/province [103] 0 0
Patras
Country [104] 0 0
Greece
State/province [104] 0 0
Thessaloniki
Country [105] 0 0
Ireland
State/province [105] 0 0
Dublin
Country [106] 0 0
Israel
State/province [106] 0 0
H_efa
Country [107] 0 0
Israel
State/province [107] 0 0
HaMerkaz
Country [108] 0 0
Israel
State/province [108] 0 0
HaTsafon
Country [109] 0 0
Israel
State/province [109] 0 0
Tel-Aviv
Country [110] 0 0
Israel
State/province [110] 0 0
Haifa
Country [111] 0 0
Italy
State/province [111] 0 0
Ancona
Country [112] 0 0
Italy
State/province [112] 0 0
Ferrara
Country [113] 0 0
Italy
State/province [113] 0 0
Genova
Country [114] 0 0
Italy
State/province [114] 0 0
Lazio
Country [115] 0 0
Italy
State/province [115] 0 0
Milano
Country [116] 0 0
Italy
State/province [116] 0 0
Roma
Country [117] 0 0
Italy
State/province [117] 0 0
Torino
Country [118] 0 0
Italy
State/province [118] 0 0
Alessandria
Country [119] 0 0
Italy
State/province [119] 0 0
Bari
Country [120] 0 0
Italy
State/province [120] 0 0
Bergamo
Country [121] 0 0
Italy
State/province [121] 0 0
Brescia
Country [122] 0 0
Italy
State/province [122] 0 0
Chieti
Country [123] 0 0
Italy
State/province [123] 0 0
Milan
Country [124] 0 0
Italy
State/province [124] 0 0
Modena
Country [125] 0 0
Italy
State/province [125] 0 0
Napoli
Country [126] 0 0
Italy
State/province [126] 0 0
Palermo
Country [127] 0 0
Italy
State/province [127] 0 0
Pavia
Country [128] 0 0
Italy
State/province [128] 0 0
Pisa
Country [129] 0 0
Italy
State/province [129] 0 0
Potenza
Country [130] 0 0
Italy
State/province [130] 0 0
Rome
Country [131] 0 0
Italy
State/province [131] 0 0
Salerno
Country [132] 0 0
Italy
State/province [132] 0 0
Siena
Country [133] 0 0
Italy
State/province [133] 0 0
Udine
Country [134] 0 0
Italy
State/province [134] 0 0
Verona
Country [135] 0 0
Kuwait
State/province [135] 0 0
Hawalli
Country [136] 0 0
Kuwait
State/province [136] 0 0
Kuwait City
Country [137] 0 0
Kuwait
State/province [137] 0 0
Kuwait
Country [138] 0 0
Mexico
State/province [138] 0 0
Ciudad De Mexico
Country [139] 0 0
Mexico
State/province [139] 0 0
Jalisco
Country [140] 0 0
Mexico
State/province [140] 0 0
Nuevo Leon
Country [141] 0 0
Mexico
State/province [141] 0 0
Mexico City
Country [142] 0 0
Mexico
State/province [142] 0 0
Puebla
Country [143] 0 0
Russian Federation
State/province [143] 0 0
Komi, Respublika
Country [144] 0 0
Russian Federation
State/province [144] 0 0
Moskovskaya Oblast
Country [145] 0 0
Russian Federation
State/province [145] 0 0
Samarskaya Oblast
Country [146] 0 0
Russian Federation
State/province [146] 0 0
Sankt-Peterburg
Country [147] 0 0
Russian Federation
State/province [147] 0 0
Tyumenskaya Oblast
Country [148] 0 0
Russian Federation
State/province [148] 0 0
Khanty-Mansyisk
Country [149] 0 0
Russian Federation
State/province [149] 0 0
Moscow
Country [150] 0 0
Russian Federation
State/province [150] 0 0
Omsk
Country [151] 0 0
Russian Federation
State/province [151] 0 0
Orenburg
Country [152] 0 0
Russian Federation
State/province [152] 0 0
Petrozavodsk
Country [153] 0 0
Russian Federation
State/province [153] 0 0
Samara
Country [154] 0 0
Russian Federation
State/province [154] 0 0
St. Petersburg
Country [155] 0 0
Russian Federation
State/province [155] 0 0
Surgut
Country [156] 0 0
Russian Federation
State/province [156] 0 0
Tomsk
Country [157] 0 0
Russian Federation
State/province [157] 0 0
Ulyanovsk
Country [158] 0 0
Russian Federation
State/province [158] 0 0
Voronezh
Country [159] 0 0
Russian Federation
State/province [159] 0 0
Yaroslavl
Country [160] 0 0
Saudi Arabia
State/province [160] 0 0
Jeddah
Country [161] 0 0
Saudi Arabia
State/province [161] 0 0
Mushait
Country [162] 0 0
Saudi Arabia
State/province [162] 0 0
Riyadh
Country [163] 0 0
Spain
State/province [163] 0 0
A Coruna
Country [164] 0 0
Spain
State/province [164] 0 0
Badajoz
Country [165] 0 0
Spain
State/province [165] 0 0
Barcelona
Country [166] 0 0
Spain
State/province [166] 0 0
Caceres
Country [167] 0 0
Spain
State/province [167] 0 0
Cadiz
Country [168] 0 0
Spain
State/province [168] 0 0
Cordoba
Country [169] 0 0
Spain
State/province [169] 0 0
Madrid
Country [170] 0 0
Spain
State/province [170] 0 0
Murcia
Country [171] 0 0
Spain
State/province [171] 0 0
Pontevedra
Country [172] 0 0
Spain
State/province [172] 0 0
Santa Cruz De Tenerife
Country [173] 0 0
Spain
State/province [173] 0 0
Zaragoza
Country [174] 0 0
Spain
State/province [174] 0 0
Almeria
Country [175] 0 0
Spain
State/province [175] 0 0
Granada
Country [176] 0 0
Spain
State/province [176] 0 0
Huelva
Country [177] 0 0
Spain
State/province [177] 0 0
Jaen
Country [178] 0 0
Spain
State/province [178] 0 0
Malaga
Country [179] 0 0
Spain
State/province [179] 0 0
Sevilla
Country [180] 0 0
Switzerland
State/province [180] 0 0
Aargau
Country [181] 0 0
Switzerland
State/province [181] 0 0
Basel-Stadt
Country [182] 0 0
Switzerland
State/province [182] 0 0
Sankt Gallen
Country [183] 0 0
Switzerland
State/province [183] 0 0
Thurgau
Country [184] 0 0
Switzerland
State/province [184] 0 0
Vaud
Country [185] 0 0
Switzerland
State/province [185] 0 0
Bern
Country [186] 0 0
Switzerland
State/province [186] 0 0
Fribourg
Country [187] 0 0
Taiwan
State/province [187] 0 0
Taipei
Country [188] 0 0
Taiwan
State/province [188] 0 0
Kaohsiung
Country [189] 0 0
Taiwan
State/province [189] 0 0
Taichung
Country [190] 0 0
Taiwan
State/province [190] 0 0
Tainan
Country [191] 0 0
Taiwan
State/province [191] 0 0
Taipei City
Country [192] 0 0
Taiwan
State/province [192] 0 0
Taoyuan City
Country [193] 0 0
United Arab Emirates
State/province [193] 0 0
Abu Dhabi
Country [194] 0 0
United Arab Emirates
State/province [194] 0 0
Dubai
Country [195] 0 0
Uruguay
State/province [195] 0 0
Montevideo

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AbbVie
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. Despite the range of treatment options for RA steadily increasing, many patients remain sub-optimally managed, with sustained clinical remission rarely achieved. This study will assess the treatment patterns, achievement of treatment targets and maintenance of response.

Upadacitinib is a drug approved for the treatment of moderately to severely active rheumatoid arthritis. Adult participants with moderate to severe RA who have been prescribed upadacitinib by their physicians will be enrolled. Approximately, 1660 participants will be enrolled this study, worldwide.

Participants will not receive Upadacitinib as part of this study, but will be followed for response to treatment for up to 24 months.

There may be higher burden for participants in this trial compared to their standard of care. Participants will attend regular visits, every 3 months, during the course of the study at a hospital or clinic and will be asked to provide additional information by questionnaire at each visit.
Trial website
https://clinicaltrials.gov/study/NCT04497597
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
ABBVIE INC.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04497597